On January 12, 2024, Adhera Therapeutics, Inc. received written notice from Melior Pharmaceuticals II, LLC of Melior's election to terminate the License Agreement dated July 28, 2021, by and between the Company and Melior with respect to the development, commercialization, and exclusive license of MLR-1019, a new class of therapeutic for Parkinson's disease. The termination of the Agreement was effective on January 12, 2024. According to Melior's termination notice, Melior determined, pursuant to the terms of the Agreement, that Adhera failed to continue commercially reasonable efforts.

Under the Agreement, the Company was granted an exclusive license to use Melior patents and know-how to develop products in consideration for cash payments upon meeting certain performance milestones as well as a royalty of 5% of gross sales.